LBCL

(redirected from Large B-Cell Lymphoma)
AcronymDefinition
LBCLLarge B-Cell Lymphoma (oncology)
LBCLLymphoblastoid B-Cell Line (cancer immunology)
LBCLLouisiana Business Corporation Law
LBCLLabatt Brewing Company Limited (Canada)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Large atypical lymphoid cells with high nuclear-cytoplasmic ratio and apoptosis, indicating transformation into an aggressive lymphoma such as diffuse large B-cell lymphoma, were partly observed (Fig.
Objective: Diffuse large B-cell lymphoma (DLBCL) is a high-grade neoplasm that has heterogeneous properties in clinical, morphological, and immunophenotypic aspects.
Most of these are reported to be plasmablastic variants of DLBCL (primary effusion lymphomas, Anaplastic lymphoma kinase positive large B-cell lymphoma, and human immunodeficiency-virus associated plasmablastic lymphoma) and have been reported to have worse outcomes compared to other DLBCL [5-7].
Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium Clinical Trials 010 and 034.
If younger patients with diffuse large B-cell lymphoma have an intensive
Serum 25-hydroxyvitamin D levels were measured in 374 patients with newly diagnosed diffuse large B-cell lymphoma. Half of the patients were found to have deficient levels of less than 25 nanograms per milliliter.
Washington, Dec 6 (ANI): The amount of vitamin D in patients being treated for diffuse large B-cell lymphoma is strongly linked to cancer progression and overall survival, according to a new study.
The aggressive NHL represent about 50% of the NHLs diagnosed in Western countries, and the most common subtype is diffuse large B-cell lymphoma. The aggressive lymphomas can arise from either B, T or NK lymphocytes.
has initiated a phase II clinical trial of SGN-40 for the treatment of patients with diffuse large B-cell lymphoma, the most common type of aggressive non-Hodgkin's lymphoma (NHL).
Schering AG, Germany is currently investigating the use of ZEVALIN in the treatment of aggressive NHL (i.e., diffuse large B-cell lymphoma) and as consolidation therapy for follicular NHL in earlier disease stages.